IBM's new partnership with research firm Boehringer Ingelheim to use fundamental artificial intelligence models to help discover new therapeutic antibodies. Antibodies are the dominant weapon in the fight against a wide range of serious diseases and have far fewer side effects than more traditional treatments. In the traditional methods of antibody production, researchers have to go through a complicated and long process, now with the help of IBM artificial intelligence, this process has become shorter and more efficient.
According to a report on IBM's website, the company wants to help produce life-saving treatments by developing a fundamental artificial intelligence model for antibody research. One of the most important challenges that hinders the development of new antibody therapies is the laboratory nature of antibody research. Successful development of a new antibody treatment requires controlled iteration, meaning that new treatments cannot be produced quickly.
Antibody production with the help of IBM artificial intelligence
Antibodies in the treatment of many diseases including Cancer, autoimmune and infectious diseases They play an essential role. Despite major advances in technology, the discovery and development of therapeutic antibodies that cover various agents is a very complex and time-consuming process.
“Fundamental models can be used for problems and data that are outside the domain of language,” said Alessandro Corioni, director of research at IBM in Zurich, at the launch of the IBM Research Lab. did.”
IBM and Boehringer Ingelheim hope to develop new antibodies using artificial intelligence Production of previously unexplored molecules And Removal of ineffective molecules, allowing researchers to focus on promising candidates. In this way, the efficiency and speed of antibody discovery increases to a great extent.
This artificial intelligence actually quickly examines the combinations with the help of data and identifies those that have fruitful results. With the help of this artificial intelligence, researchers can focus on more valuable things.
RCO NEWS